Sarepta Therapeutics' (SRPT) "Neutral" Rating Reaffirmed at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "neutral" rating restated by stock analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $40.00 price target on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 1.27% from the stock's current price.

Other research analysts have also recently issued research reports about the company. Oppenheimer lowered their price objective on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Royal Bank of Canada lowered their price objective on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price objective on Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 20th. The Goldman Sachs Group lowered their price objective on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company decreased their price target on Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $122.61.

Sarepta Therapeutics Stock Performance

SRPT traded up $1.60 during trading hours on Thursday, reaching $39.50. The company's stock had a trading volume of 1,856,892 shares, compared to its average volume of 1,788,385. Sarepta Therapeutics has a 52 week low of $34.10 and a 52 week high of $173.25. The company's 50-day moving average is $53.76 and its 200-day moving average is $93.63. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $3.88 billion, a PE ratio of 31.60 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter last year, the company posted $0.73 EPS. The firm's revenue was up 80.2% on a year-over-year basis. On average, equities analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Capital International Investors increased its holdings in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares in the last quarter. Norges Bank bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $126,315,000. Assenagon Asset Management S.A. grew its holdings in Sarepta Therapeutics by 438.0% during the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock worth $45,477,000 after buying an additional 580,123 shares in the last quarter. Wellington Management Group LLP grew its holdings in Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after buying an additional 577,848 shares in the last quarter. Finally, EcoR1 Capital LLC grew its holdings in Sarepta Therapeutics by 67.8% during the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock worth $82,480,000 after buying an additional 522,386 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.